Generic manufacturer Mylan will not sell Dey L.P., its specialty pharmaceutical division. After a review, the company decided Dey L.P. would be positive for earnings through 2010.
Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.
Illinois may be tempted to offer tax incentives for the firm to stay put.
FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.